{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Standard+ADT", "query": { "intervention": "Standard ADT" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 95, "total_pages": 10, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Standard+ADT&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-11T16:53:14.566Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01985828", "title": "CyberKnife® as Monotherapy or Boost SBRT for Intermediate or High Risk Localized Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Prostate Adenocarcinoma" ], "interventions": [ { "name": "CyberKnife", "type": "RADIATION" }, { "name": "Androgen Deprivation Therapy (ADT)", "type": "OTHER" }, { "name": "Intensity Modulated radiation therapy (IMRT)", "type": "RADIATION" } ], "intervention_types": [ "RADIATION", "OTHER" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 83, "start_date": "2013-11-19", "completion_date": "2019-08", "has_results": true, "last_update_posted_date": "2024-10-03", "last_synced_at": "2026-09-11T16:53:14.566Z", "location_count": 1, "location_summary": "Park Ridge, Illinois", "locations": [ { "city": "Park Ridge", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01985828" }, { "nct_id": "NCT03689699", "title": "Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Prostate Cancer", "Adenocarcinoma of the Prostate" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" }, { "name": "Degarelix", "type": "DRUG" }, { "name": "BMS-986253", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mark Stein", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "MALE", "summary": "18 Years to 99 Years · Male only" }, "enrollment_count": 59, "start_date": "2018-10-11", "completion_date": "2026-01", "has_results": true, "last_update_posted_date": "2025-04-29", "last_synced_at": "2026-09-11T16:53:14.566Z", "location_count": 4, "location_summary": "Atlanta, Georgia • New York, New York • Philadelphia, Pennsylvania", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03689699" }, { "nct_id": "NCT07206056", "title": "An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Progressive Metastatic Castrate Resistant Prostate Cancer" ], "interventions": [ { "name": "Tulmimetostat DL1 QD", "type": "DRUG" }, { "name": "Tulmimetostat DL2 QD", "type": "DRUG" }, { "name": "Tulmimetostat DL3 QD", "type": "DRUG" }, { "name": "Tulmimetostat Doses 1 or 2 QD", "type": "DRUG" }, { "name": "Tulmimetostat RP2D QD", "type": "DRUG" }, { "name": "JSB462 Dose 1 QD", "type": "DRUG" }, { "name": "JSB462 Dose 2 QD", "type": "DRUG" }, { "name": "JSB462 QD", "type": "DRUG" }, { "name": "Standard of Care (SoC)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 188, "start_date": "2025-10-15", "completion_date": "2030-12-01", "has_results": false, "last_update_posted_date": "2026-08-21", "last_synced_at": "2026-09-11T16:53:14.566Z", "location_count": 8, "location_summary": "Denver, Colorado • Jacksonville, Florida • Atlanta, Georgia + 5 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Wichita", "state": "Kansas" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07206056" }, { "nct_id": "NCT03739203", "title": "The Objective of This Study is to Evaluate the Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants Alone", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Major Depressive Disorder" ], "interventions": [ { "name": "Cariprazine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Antidepressant Therapy (ADT)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 752, "start_date": "2018-11-10", "completion_date": "2021-09-06", "has_results": true, "last_update_posted_date": "2022-09-21", "last_synced_at": "2026-09-11T16:53:14.566Z", "location_count": 58, "location_summary": "Dothan, Alabama • Little Rock, Arkansas • Anaheim, California + 50 more", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Colton", "state": "California" }, { "city": "Costa Mesa", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03739203" }, { "nct_id": "NCT02168062", "title": "Supportive Therapy in Androgen Deprivation Clinic in Improving Health Outcomes and Managing Side Effects in Patients With Prostate Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Adenocarcinoma" ], "interventions": [ { "name": "Behavioral Dietary Intervention", "type": "BEHAVIORAL" }, { "name": "Counseling", "type": "OTHER" }, { "name": "Educational Intervention", "type": "OTHER" }, { "name": "Exercise Intervention", "type": "BEHAVIORAL" }, { "name": "Goserelin Acetate", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Leuprolide Acetate", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Triptorelin Pamoate", "type": "DRUG" } ], "intervention_types": [ "BEHAVIORAL", "OTHER", "DRUG" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "MALE", "summary": "Male only" }, "enrollment_count": 57, "start_date": "2014-06-16", "completion_date": "2018-05-22", "has_results": true, "last_update_posted_date": "2020-07-23", "last_synced_at": "2026-09-11T16:53:14.566Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02168062" }, { "nct_id": "NCT06312670", "title": "Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Hormone-sensitive Prostate Cancer (mHSPC)", "Prostate Cancer", "Prostate Adenocarcinoma" ], "interventions": [ { "name": "EPI-7386", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Androgen Deprivation Therapy (ADT)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pedro Barata, MD, MSc", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "MALE", "summary": "19 Years and older · Male only" }, "enrollment_count": 13, "start_date": "2024-05-16", "completion_date": "2025-01-09", "has_results": false, "last_update_posted_date": "2025-05-29", "last_synced_at": "2026-09-11T16:53:14.566Z", "location_count": 2, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT06312670" }, { "nct_id": "NCT02312401", "title": "Evaluation of Treatment Response Using Multiparametric MRI After Prostate Radiotherapy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "multi-parametric MRI(MP-MRI)", "type": "DEVICE" }, { "name": "dynamic contrast-enhanced MRI (DCE)", "type": "DEVICE" }, { "name": "biopsy", "type": "PROCEDURE" } ], "intervention_types": [ "DEVICE", "PROCEDURE" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 120, "start_date": "2014-12", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-01-29", "last_synced_at": "2026-09-11T16:53:14.566Z", "location_count": 8, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02312401" }, { "nct_id": "NCT04037254", "title": "Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Prostate Adenocarcinoma", "Stage IIC Prostate Cancer AJCC v8", "Stage III Prostate Cancer AJCC v8", "Stage IIIA Prostate Cancer AJCC v8", "Stage IIIB Prostate Cancer AJCC v8", "Stage IIIC Prostate Cancer AJCC v8", "Stage IVA Prostate Cancer AJCC v8" ], "interventions": [ { "name": "Gonadotrophin Releasing Hormone", "type": "BIOLOGICAL" }, { "name": "Intensity-Modulated Radiation Therapy", "type": "RADIATION" }, { "name": "Niraparib", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "RADIATION", "DRUG" ], "sponsor": "NRG Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 22, "start_date": "2019-10-08", "completion_date": "2025-12-23", "has_results": true, "last_update_posted_date": "2026-07-10", "last_synced_at": "2026-09-11T16:53:14.566Z", "location_count": 94, "location_summary": "Gilbert, Arizona • Tucson, Arizona • Duarte, California + 77 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04037254" }, { "nct_id": "NCT06952803", "title": "A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Saruparib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Abiraterone + Prednisolone/Prednisone", "type": "DRUG" }, { "name": "Androgen Deprivation Therapy (ADT)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 700, "start_date": "2025-08-06", "completion_date": "2036-04-30", "has_results": false, "last_update_posted_date": "2026-08-21", "last_synced_at": "2026-09-11T16:53:14.566Z", "location_count": 45, "location_summary": "Phoenix, Arizona • Tucson, Arizona • La Jolla, California + 40 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06952803" }, { "nct_id": "NCT05348577", "title": "Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "capivasertib", "type": "DRUG" }, { "name": "docetaxel", "type": "DRUG" }, { "name": "placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "MALE", "summary": "18 Years to 130 Years · Male only" }, "enrollment_count": 1035, "start_date": "2022-03-25", "completion_date": "2026-03-04", "has_results": false, "last_update_posted_date": "2025-01-27", "last_synced_at": "2026-09-11T16:53:14.566Z", "location_count": 37, "location_summary": "Yuma, Arizona • Beverly Hills, California • Cerritos, California + 31 more", "locations": [ { "city": "Yuma", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Cerritos", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05348577" } ] }